Q2 EPS Estimate for Y-mAbs Therapeutics Lowered by Analyst

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Stock analysts at HC Wainwright reduced their Q2 2025 earnings per share estimates for shares of Y-mAbs Therapeutics in a report issued on Monday, May 19th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.23) per share for the quarter, down from their previous estimate of ($0.22). HC Wainwright currently has a "Buy" rating and a $11.00 target price on the stock. The consensus estimate for Y-mAbs Therapeutics' current full-year earnings is ($0.65) per share. HC Wainwright also issued estimates for Y-mAbs Therapeutics' Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($0.80) EPS, Q1 2026 earnings at ($0.24) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.22) EPS and Q4 2026 earnings at ($0.23) EPS.

Other equities analysts have also recently issued research reports about the company. Wedbush restated an "outperform" rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. Truist Financial dropped their price target on Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Morgan Stanley dropped their price target on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a research report on Wednesday, March 5th. Oppenheimer dropped their price target on Y-mAbs Therapeutics from $21.00 to $20.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 14th. Finally, Bank of America cut Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price target on the stock. in a research report on Tuesday, April 22nd. Two equities research analysts have rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $16.60.

Y-mAbs Therapeutics Stock Up 4.6%

YMAB stock traded up $0.19 during trading on Wednesday, hitting $4.32. The company had a trading volume of 324,293 shares, compared to its average volume of 311,779. The firm has a market cap of $195.63 million, a PE ratio of -8.00 and a beta of 0.53. Y-mAbs Therapeutics has a 1-year low of $3.55 and a 1-year high of $16.11. The firm has a 50-day moving average price of $4.41 and a 200-day moving average price of $6.74.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.10. The firm had revenue of $20.90 million for the quarter, compared to analysts' expectations of $19.97 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Principal Financial Group Inc. grew its holdings in shares of Y-mAbs Therapeutics by 9.4% in the 4th quarter. Principal Financial Group Inc. now owns 22,197 shares of the company's stock worth $174,000 after acquiring an additional 1,903 shares during the period. Rhumbline Advisers grew its holdings in shares of Y-mAbs Therapeutics by 4.8% in the 1st quarter. Rhumbline Advisers now owns 53,909 shares of the company's stock worth $239,000 after acquiring an additional 2,457 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Y-mAbs Therapeutics by 12.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,818 shares of the company's stock worth $179,000 after acquiring an additional 2,545 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Y-mAbs Therapeutics by 10.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company's stock worth $399,000 after acquiring an additional 2,854 shares during the period. Finally, SG Americas Securities LLC grew its holdings in shares of Y-mAbs Therapeutics by 30.7% in the 4th quarter. SG Americas Securities LLC now owns 17,729 shares of the company's stock worth $139,000 after acquiring an additional 4,163 shares during the period. Institutional investors and hedge funds own 70.85% of the company's stock.

Insiders Place Their Bets

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of the business's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $5.23, for a total transaction of $56,536.30. Following the transaction, the insider now owns 202,721 shares in the company, valued at approximately $1,060,230.83. The trade was a 5.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 22.50% of the stock is currently owned by insiders.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.